

Therapeutics Advisory Group Update - Issue 23 – June 2023

All recommendations discussed at the **June** TAG and D+TC meetings and ratified by the Planned Care and Medicines Management Working Group on behalf of the ICB – **June 2023**. Please share within your organisation as appropriate.

Commissioning Summary

<p>Formulary application - Weekly adalimumab (biosimilar) for dose escalations in NICE-approved rheumatology indications (NWICB local decision)</p>	<p>Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care</p>
<p>Formulary application - Roxadustat for treatment of symptomatic anaemia in chronic kidney disease (CKD stage 3 to 5 with no iron deficiency and not on dialysis at the start of treatment) as per TA807</p>	
<p>Formulary application - Tralokinumab for treatment of moderate to severe atopic dermatitis in adults who are candidates for systemic therapy as per TA814</p>	
<p>Formulary application - Upadacitinib for treating active non-radiographic axial spondyloarthritis as per TA861</p>	
<p>Formulary application - Upadacitinib for moderate to severe atopic dermatitis as per TA814</p>	
<p>Formulary application - Lyumjev (Insulin Lispro) insulin for adults with type 1 and type 2 diabetes</p>	<p>ADVICE - Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation See Netformulary entry for full information</p>
<p>Commissioning Review - Propafenone for cardiovascular indications</p>	<p>Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care</p>
<p>Commissioning Review - Methadone for pain management in COMPLEX patients:</p> <ul style="list-style-type: none"> • Refractory neuropathic pain • Severe, iatrogenic opioid dependence patients • Patients with chronic pain response to doses of strong opioid 	<p>Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care</p> <p>Please note: Patients who are currently receiving methadone prescriptions in primary care and are STABLE should continue to do so. Do not re-refer to pain clinic. Contact the pain clinic only where further advice is required.</p>
<p>Netformulary Updates</p> <ul style="list-style-type: none"> • Ogluo® branded glucagon - BLACK as more expensive than current first choice glucagon preparation so potential cost-pressure. Glucagon out of stock until mid-July so message added to Netformulary providing additional guidance • Blue traffic light classification wording updated to NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required • We have several sections live on Netformulary. If you have any formulary queries, please remember to check there first before emailing the generic inbox 	

Shared Care Updates

Updated Shared Care Agreements <ul style="list-style-type: none"> Hydroxycarbamide (RMOC) Melatonin for sleep disorders 	Supported by the TAG Published on Netformulary and Knowledge Anglia
Shared Care Agreements under review <ul style="list-style-type: none"> Hydroxychloroquine (RMOC) Low Molecular Weight Heparin 	To return to a future TAG meeting for discussion

NICE Guidance – acknowledged by the TAG

NG122 – March 2019, updated March 2023 - Lung cancer: diagnosis and management
NG191 – March 2021, updated March 2023 - COVID-19 rapid guideline: managing COVID-19
NG101 – July 2018, updated March 2023 - Early and locally advanced breast cancer: diagnosis and management
NG133 – June 2019, updated April 2023 - Hypertension in pregnancy: diagnosis and management
CG104 – July 2010, updated April 2023 - Metastatic malignant disease of unknown primary origin in adults: diagnosis and management
NG18 – August 2015, updated May 2023 - Diabetes (type 1 and type 2) in children and young people: diagnosis and management
NG198 – June 2021, updated May 2023 - Acne vulgaris: management
NG232 – May 2023 - Head injury: assessment and early management
CG181- July 2014, updated May 2023 - Cardiovascular disease: risk assessment and reduction, including lipid modification

NICE Technology Appraisals – ICB Commissioning Responsibility

TA875 – March 2023 - Semaglutide (Wegovy®) for managing overweight and obesity	<p>BLUE – NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required</p> <p>RED/HOSPITAL - Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care</p> <p>Noted. To be discussed at TAG meeting in July</p>
TA877- March 2023 - Finerenone (Kerendia®) for treating chronic kidney disease in type 2 diabetes	
TA888 – May 2023 - Risankizumab (Skyrizi®) for previously treated moderately to severely active Crohn's disease (This technology is commissioned by integrated care boards for people aged 18 and over and by NHS England for people aged 16 to 17)	
TA871 – March 2023 - Eptinezumab (VYEPTI®) for preventing migraine	
TA880 – April 2023 - Tezepelumab (Tezspire®) for treating severe asthma	
TA878 – April 2023 - Casirivimab plus imdevimab (Ronapreve®), nirmatrelvir plus ritonavir (Paxlovid®), sotrovimab (Xevudy®) and tocilizumab (RoActemra®) for treating COVID-19	

NICE Technology Appraisals – NHS England Commissioning Responsibility

<p>TA872 – February 2023 - Axicabtagene ciloleucel (Yescarta®) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (Replaces TA559)</p>	<p>RED/HOSPITAL - Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care</p>
<p>TA873 – March 2023 - Cannabidiol (Epidyolex®) for treating seizures caused by tuberous sclerosis complex</p>	
<p>TA874 – March 2023 - Polatuzumab vedotin (Polivy®) in combination for untreated diffuse large B-cell lymphoma</p>	
<p>TA876 – March 2023 - Nivolumab (Opdivo®) with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer</p>	
<p>TA882 – May 2023 - Voclosporin (Lupkynis®) with mycophenolate mofetil for treating lupus nephritis</p>	
<p>TA885 – May 2023 - Pembrolizumab (Keytruda®) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer</p>	
<p>TA886 – May 2023 - Olaparib (Lynparza®) for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy</p>	
<p>TA887 – May 2023 - Olaparib (Lynparza®) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer</p>	
<p>TA890 – May 2023 - Difelikefalin (Kapruvia®) for treating pruritus in people having haemodialysis</p>	<p>BLACK - Not commissioned. No NHS prescribing in primary or secondary care. Not recommended by NICE</p>
<p>TA881 – May 2023 - Ripretinib (Qinlock®) for treating advanced gastrointestinal stromal tumour after 3 or more treatments</p>	
<p>TA883 – May 2023 - Tafasitamab (Minjuvi®) with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma</p>	

NICE Technology Appraisals – Terminated Appraisals

<p>TA879 – April 2023 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment</p>	<p>BLACK - Not commissioned. No NHS prescribing in primary or secondary care. Not recommended by NICE</p>
<p>TA884 – May 2023 - Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping</p>	
<p>TA889 – May 2023 - Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma</p>	
<p>TA879 – April 2023 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment</p>	
<p>TA884 – May 2023 - Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping</p>	

NICE Technology Appraisals – NHS England Highly Specialised Technologies

HST23 – March 2023 - Asfotase alfa (Strensiq®) for treating paediatric-onset hypophosphatasia	RED/HOSPITAL - Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care
HST25 – April 2023 - Lumasiran (Oxlumo®) for treating primary hyperoxaluria type 1	
HST26 – April 2023 - Eladocagene exuparvovec (Upstaza®) for treating aromatic L-amino acid decarboxylase deficiency	
HST15 – July 2021, updated April 2023 - Onasemnogene abeparvovec (Zolgensma®) for treating spinal muscular atrophy	
HST24 – April 2023 - Onasemnogene abeparvovec (Zolgensma®) for treating presymptomatic spinal muscular atrophy	

Future TAG Meetings

Meetings will be held on the **first Wednesday of the month** virtually **via Microsoft Teams**. In between these meetings, essential items may be emailed to committee members for comments

Meetings to be held from 2.00pm

Agenda and supporting documents will be sent to members the Wednesday before the TAG meeting

Meeting Dates	Deadline for Agenda Items
Wednesday 5 th July 2023	Tuesday 27 th June 2023
Wednesday 2 nd August 2023	August meeting cancelled due to summer holidays
Wednesday 6 th September 2023	Tuesday 29 th August 2023
Wednesday 4 th October 2023	Tuesday 26 th September 2023
Wednesday 1 st November 2023	Tuesday 24 th October 2023
Wednesday 6 th December 2023	Tuesday 28 th November 2023